Les Meilleurs doctors pour le traitement de thrombocytopénie à Ramat Gan - TOP-5 des médecins

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Prof. Elad Jacoby, MD

Global Leader in Pediatric Hemato-Oncology, CAR-T Therapy & Bone Marrow Transplantation

About Prof. Elad Jacoby

Prof. Elad Jacoby is one of the world’s leading experts in pediatric hemato-oncology and advanced cellular therapies, serving as the Head of the Pediatric Cell Therapy Center and Medical Director of the Advanced Biotherapy Center at Sheba Medical Center. With nearly two decades of clinical and research experience, he is widely recognized for transforming the treatment landscape for children with complex and treatment-resistant blood cancers.

Prof. Jacoby is a pioneer of CAR-T cell therapy in Israel, having led the implementation of one of the first national programs for pediatric leukemia. His work focuses on delivering highly personalized, cutting-edge therapies to children who often have limited or no remaining standard treatment options.

Beyond his clinical leadership, he is an Associate Professor at Tel Aviv University, actively involved in training the next generation of physicians while leading groundbreaking international research in immunotherapy and cellular medicine.

Clinical Expertise & Special Focus

Prof. Jacoby specializes in the most advanced and life-saving treatments for children and young patients with hematologic malignancies, including:

• CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cells)
  Personalized immunotherapy designed to reprogram the patient’s immune system to fight cancer
• Bone Marrow & Stem Cell Transplantation (BMT)
  Including complex and high-risk transplant cases
• Pediatric Leukemia & Lymphoma
  Acute lymphoblastic leukemia (ALL), relapsed/refractory leukemias, and aggressive lymphomas
• Advanced Cellular Immunotherapy
  Including anti-viral T-cell therapies for immunocompromised patients
• Mitochondrial Augmentation Therapy (MAT)
  First-in-human innovative treatments for rare and complex conditions

His approach combines precision medicine, immunotherapy, and transplantation, allowing for comprehensive, individualized care even in the most challenging cases.

Innovation & Research Leadership

Prof. Jacoby is at the forefront of global innovation in pediatric cancer care. He leads and participates in international clinical trials focused on next-generation therapies, including:

• CAR-T therapies for resistant leukemias and lymphomas
• Novel cellular therapies targeting cancer and severe infections
• Breakthrough research in mitochondrial medicine and immune system modulation

He has authored over 240 scientific publications in leading medical journals and collaborates with top institutions worldwide, including:

• Johns Hopkins Hospital (USA)
• National Cancer Institute (NCI), USA
• International pediatric oncology and CAR-T research networks

His research directly translates into real-world treatment options, giving patients access to therapies not widely available elsewhere.

Patient-Centered Approach

Prof. Jacoby is known not only for his clinical excellence but also for his deep commitment to patient-centered care. Every child and family receives:

• A fully personalized treatment plan tailored to the disease and patient profile
• Access to the most advanced therapies available globally
• Close monitoring by a multidisciplinary team of experts
• Compassionate guidance throughout every stage of treatment

His philosophy is simple: combine innovation with empathy, ensuring that families feel supported, informed, and confident in their care journey.

Leadership & Roles

• Head, Pediatric Cell Therapy Center, Sheba Medical Center
• Medical Director, Advanced Biotherapy Center, Sheba Medical Center
• Senior Lecturer / Associate Professor, Tel Aviv University School of Medicine
• Member, CAR-T Cell Taskforce (IBFM Study Group)
• Member, Institutional Review Board, Sheba Medical Center

Education & International Training

• MD, Tel Aviv University School of Medicine
• Pediatrics Residency, Sheba Medical Center
• Fellowship in Pediatric Hematology & Oncology, Johns Hopkins Hospital, USA
• Clinical & Research Fellowship, National Cancer Institute (NCI), USA

Board Certifications

• Pediatrics
• Pediatric Hematology & Oncology

Why Patients Choose Prof. Elad Jacoby

• Pioneer of pediatric CAR-T therapy in Israel
• Leader in integrating CAR-T with bone marrow transplantation
• Access to exclusive clinical trials and next-generation treatments
• Extensive experience in complex and relapsed cases
• Internationally recognized expert with a strong academic and research background
• Dedicated to delivering hope through innovation and personalized care

A Leader in the Future of Pediatric Cancer Care

Through his work, Prof. Jacoby continues to redefine what is possible in treating childhood cancers—bringing together science, innovation, and compassionate care to improve outcomes and give new hope to patients and their families worldwide.